Will circumcision provide even more protection from HIV to women and men? New estimates of the population impact of circumcision interventions

Timothy B Hallett,1 Ramzi A Alsallaq,2 Jared M Baeten,3 Helen Weiss,4 Connie Celum,3 Ron Gray,5 Laith Abu-Raddad2 6 7

ABSTRACT

Background Mathematical modelling has indicated that expansion of male circumcision services in high HIV prevalence settings can substantially reduce population-level HIV transmission. However, these projections need revision to incorporate new data on the effect of male circumcision on the risk of acquiring and transmitting HIV.

Methods Recent data on the effect of male circumcision during wound healing and the risk of HIV transmission to women were synthesised based on four trials of circumcision among adults and new observational data of HIV transmission rates in stable partnerships from men circumcised at younger ages. New estimates were generated for the impact of circumcision interventions in two mathematical models, representing the HIV epidemics in Zimbabwe and Kismu, Kenya. The models did not capture the interaction between circumcision, HIV and other sexually transmitted infections.

Results An increase in the risk of HIV acquisition and transmission during wound healing is unlikely to have a major impact of circumcision interventions. However, it was estimated that circumcision confers a 46% reduction in the rate of male-to-female HIV transmission. If this reduction begins 2 years after the procedure, the benefit much more from circumcision interventions than had previously been predicted, and these results provide an even greater imperative to increase scale-up of safe male circumcision services.

BACKGROUND

Since three randomised controlled trials demonstrated that adult male circumcision reduces men’s chance of HIV acquisition by about 60%,1–3 there has been substantial interest in developing and expanding services that provide male circumcision as an additional HIV prevention strategy.4 An important part of the planning and strategic decision-making process for expanding circumcision services has been quantifying the expected impact such interventions might have on the rate of new HIV infections in populations, and several mathematical models have been developed to generate estimates.5–9 To guide HIV prevention policy decisions, these estimates are compared with others that evaluate different prevention strategies, such as scaling-up testing and counselling services,10 11 campaigns with messages about abstinence, condom use and reducing multiple partners,12 13 and universal HIV testing with immediate initiation of antiretroviral therapy (ie, ‘Universal Test and Treat’).14 15

Previous modelling of the impact of male circumcision on population-level HIV had two important limitations: lack of data about the rate of HIV transmission (both female-to-male and male-to-female) before the wound has healed, and the long-term effect of male circumcision on risk of male-to-female transmission. We hypothesised that these limitations resulted in substantial imprecision in the estimate of the impact of circumcision interventions on HIV spread, both overall and especially among women.

Recently, new data have become available to address these limitations. A pooled analysis from the three trials evaluating the effect of male circumcision on female-to-male HIV transmission found that sex before the wound has healed was associated with a transient increased risk of HIV acquisition in men.16 In addition, two recent studies have reported on the relationship between male circumcision and male-to-female HIV transmission. The first, a randomised trial of circumcision from Uganda, found no short-term benefit of circumcision (ie, to 24 months after the operation) and some suggestion of increased HIV transmission risk to women from circumcised HIV-infected men who resumed sex before the wound was healed.17 The second, an observational analysis from a cohort of 3408 HIV-discordant couples from 14 sites in eastern and southern Africa followed for up to 2 years, found that male-to-female HIV transmission risk was 41% lower from circumcised men compared with uncircumcised men (relative transmission rate of 0.59 (95% CI 0.31 to 1.13); the corresponding estimate adjusted for viral load is: 0.60 (95% CI 0.31 to 1.16)).18 These data mirror those from an earlier observational study in Rakai, Uganda that found a relative male-to-female HIV transmission rate of 0.41 (95% CI 0.10 to 1.14) in couples with circumcised versus uncircumcised HIV-infected men.19 Together, these data suggest that association between circumcision and male-to-female HIV transmission risk is influenced by the timing of circumcision, with recent circumcision offering no benefit, but circumcision at an earlier age (and thus a longer interval between surgery to sex) significantly reducing HIV transmission risk to female partners.
To explore the implications of these new observations for the estimates of the potential impact of circumcision interventions, we adapted two previous published mathematical models—by Hallett et al for Zimbabwe and Alsallaq et al for Kisumu, Kenya.

METHODS

Full descriptions of the two mathematical models have already been published, and brief descriptions are provided here.

Model 1: Zimbabwe (Hallett et al)

This model is a deterministic compartmental representation of the heterosexual spread of HIV in Zimbabwe, with HIV prevalence of ~20% and initially low rates of circumcision. To capture the heterogeneity in the number of sexual partners, men and women in the model were stratified into risk groups. Men and women form partnerships so that it is more likely that high-risk individuals form partnerships with one another. Published data from eastern Zimbabwe were used to inform these parameters specifying sexual behaviour (although the broad behavioural patterns are similar to reports in other settings). Based on observational data from other longitudinal studies, the course of infection is represented by individuals progressing through several stages: acute infection (short duration, high infectiousness), latent infection (long duration, low infectiousness) and pre-AIDS (short duration, high infectiousness). The Zimbabwe model was fitted to both the antenatal clinic prevalence data and the Demographic and Health Surveys prevalence estimate.

Model 2: Kisumu, Kenya (Alsallaq et al)

This model is a deterministic compartmental representation of the heterosexual spread of HIV in Kisumu, Kenya calibrated by three sets of prevalence data: the Four City study population survey data, the Kenya AIDS indicator survey data for Kisumu, and the ANC surveillance data. Before the intervention, HIV prevalence is ~15%, and 25% of adult men are circumcised. A hierarchy of effective rates of partnership formation were used as a surrogate of sexual risk to stratify the population into four sexual-risk groups. The effective rates of partnership formation were used as a surrogate of sexual risk to stratify the population into four sexual-risk groups. The effective rates of partnership formation for females were assumed to balance participation in sexual partnerships. The reduction in the rate of HIV transmission before wound is healed decreases over time, so the long-term effect of the circumcision wound healing period is likely to be even less.

RESULTS

Firstly, we explored the potential impact of the risk of HIV acquisition and transmission being higher during the wound healing period. In a hypothetical intervention that reduced the proportion of the population that are uncircumcised to 50% over 10 years and in which no men resume sex during wound healing, the HIV incidence rate (new infections per person-years at risk) in the whole population after 10 years is reduced by 20.5% in Zimbabwe (0% circumcised before intervention) and by 7.4% in Kisumu (25% circumcised before intervention). Alternatively, making the most pessimistic assumptions that all men remain sexually active throughout the wound healing period and the mean duration of wound healing is as long as six weeks, the incidence rate is still projected to decrease by 19% in Zimbabwe and 6.2% in Kisumu over the same period. Differences between the simulations decrease over time, so the long-term effect of the elevated chance of HIV acquisition and transmission during the circumcision wound healing period is likely to be even less.

We next conducted a meta-analysis of data from the two independent observational cohorts on the long-term effect of male circumcision on male-to-female HIV transmission. The overall fixed-effect point-estimate hazard rate was 0.54 (95% CI 0.31 to 0.96) (p=0.04), indicating 46% reduction in transmission rate from 2 years after the operation. There was no evidence for heterogeneity in effect size (p=0.61).

On the basis of the meta-analysis results, we explored the impact of the reduction in the rate of transmission from circumcision interventions on the rate of HIV transmission.

Table 1: Parameters specifying the effect of male circumcision on the rate of HIV transmission (ranges used in the uncertainty analysis are presented in table S1 in the online technical appendix)

<table>
<thead>
<tr>
<th>Parameter description</th>
<th>Value</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean duration of wound healing period</td>
<td>14 days (95% healed within 6 weeks).</td>
<td>34</td>
</tr>
<tr>
<td>Change in the rate of female-to-male HIV transmission before wound is healed versus before circumcision</td>
<td>Increases 3-fold</td>
<td>16</td>
</tr>
<tr>
<td>Change in rate of HIV male-to-female HIV transmission before wound is healed versus before circumcision</td>
<td>Increases 3.5-fold</td>
<td>17</td>
</tr>
<tr>
<td>Proportion of men who remain sexually active during the wound healing period</td>
<td>13%</td>
<td>16</td>
</tr>
<tr>
<td>Change in rate of female-to-male HIV transmission after the wound has healed versus before circumcision</td>
<td>Decreases by 65%</td>
<td>35</td>
</tr>
<tr>
<td>Change in rate of male-to-female HIV transmission before 2 years after the operation versus before circumcision</td>
<td>No effect</td>
<td>17</td>
</tr>
<tr>
<td>Change in rate of male-to-female HIV transmission from 2 years after the operation versus before circumcision</td>
<td>We estimated this after performing a meta-analysis of data from the two studies among HIV sero-discordant couples that measured this effect</td>
<td>18 19</td>
</tr>
</tbody>
</table>
circumcised HIV-infected men to their uninfected female partners, after the wound healing period and the subsequent 2 years (as defined in the Methods). Assuming first no effect of circumcision on male-to-female transmission and using best estimates for the duration of wound healing (table S1), our simulations suggest that the incidence rate would decrease by 19.8% in Zimbabwe or 9.4% in Kisumu after 20 years. Then, assuming an estimated 46% reduction in male-to-female transmission rate associated with circumcision, starting 2 years after the procedure, corresponding estimates for the reduction in incidence are 28.0% (Zimbabwe) and 16.8% (Kisumu) (figure 1A,B). This is an increase in epidemiological impact of at least 40% overall.

As expected, the reduction in incidence with the male-to-female transmission effect is most enhanced among women (figure 1C,D). Without an effect of circumcision on male-to-female HIV transmission, incidence is reduced among women by 11.7% in Zimbabwe or 5.9% in Kisumu after 20 years; but, with the direct effect on male-to-female transmission, incidence is instead reduced by 23.7% (Zimbabwe) or 13.9% (Kisumu). Thus the epidemiological impact among women at least almost doubles.

The number of operations required for each HIV infection averted is also substantially reduced if there is a long-term reduction in male-to-female transmission of HIV as a result of male circumcision: in Zimbabwe, from 11 operations per infection averted after 20 years if there is no effect on transmission to eight operations (down 28%); and, in Kisumu, from 14 operations per infection to eight operations over the same period (down 41%).

The multivariate uncertainty was used to determine how the uncertainty in the estimated effects of circumcision propagates to the projections in epidemiological impact (Zimbabwe model only, but qualitatively similar results would be expected for the Kisumu model). With the original assumptions (no effect of wound healing and no effect on male-to-female HIV transmission), the uncertainty intervals for the reduction in incidence after 20 years are 15–32% overall and 9–21% among women. The new empirical data (table S1) supports the updated estimates of 22–43% reduction in incidence overall, and a 15–39% reduction among women (figure 2).

If there is no effect of circumcision on male-to-female transmission and a moderate degree of increased risk behaviour following the operation, then it is possible that HIV incidence among women and the population overall could increase following the intervention (online supplementary figure S1)—a serious adverse outcome. However, assuming a 46% reduction in the transmission rate with circumcision (2 years after the operation), then our modelling suggests that even very high degrees of increased risk among circumcised men would not lead to increases in incidence overall under the intervention.

DISCUSSION

Our synthesis of new data about the effect of circumcision on female-to-male and male-to-female HIV transmission provides an even greater imperative to increase scale-up of circumcision interventions to prevent HIV. We found that (a) a transient increased risk of HIV transmission (in both directions) during
the circumcision wound healing period resulted in only a negligible effect on HIV incidence rate in populations, (b) potential long-term reduced risk of HIV transmission from HIV-infected circumcised men amplified the benefits of circumcision implementation, and (c) the benefits of circumcision in these scenarios were particularly great for women.

While short-term increased risk for both female-to-male and male-to-female HIV transmission may occur while the wound heals, this effect is very unlikely to materially affect the impact of circumcision interventions at the population level. Nonetheless, careful communication strategies should still be used to promote abstinence for at least 2 months after the operation to minimise the chance of HIV transmission to female partners.

Our meta-analysis of the best available cohort data suggests that male circumcision reduces the chance of male-to-female HIV transmission with a latent interval of at least 2 years, and that this substantially amplifies the potential impact of circumcision interventions in populations. Our new projections for the reduction in HIV incidence following circumcision interventions are 40% greater in Zimbabwe and 79% greater for Kisumu, and the number of operations required per infection averted is reduced by more than 25%, when the overall benefit in reduced HIV male-to-female transmission was included. This increases the already attractive cost-saving potential of circumcision interventions. (In the online supplementary text S1, we have also provided a simple formula for making a calculation of operations per infection averted—ie, generalised to other settings.) Indeed, the combination of the two separate effects of circumcision (reducing the chance that men acquire HIV infection and reducing the chance that infected men pass on HIV infection) leads to a more powerful effect than would be expected on the basis of considering the two effects separately (figure S2).

Importantly, our simulations show very significantly that the benefit of circumcision interventions to women is greatly increased. Although it was previously expected that women would benefit modestly from male circumcision implementation (as fewer of their sexual partners would be infected), these new projections show that women could also receive a direct benefit from circumcision. Earlier work had predicted that the population impact of circumcision intervention would be sensitive to this factor. If our estimate about the long-term effect of circumcision on male-to-female transmission is correct, then women in stable partnerships with infected men would receive a degree of protection from circumcision similar to that received by men in partnerships with infected women. We note, however, that the standard of evidence for an effect on male-to-female transmission (meta-analysis of two cohort studies) is much less than that for the effect of circumcision on men’s chance of acquiring HIV infection (three randomised trials and more than 36 observational studies). Our results do not indicate that HIV-infected men should be targeted for circumcision, as most of the impact of the reduction in male-to-female transmission comes through reducing onward transmission of ‘break-through’ infections among men circumcised when they were not infected (if only uninfected men are circumcised in the intervention, the eventual reduction in incidence is increased by 30% overall and 66% for women, compared with 44% and 95%, respectively, if HIV-infected men are circumcised too). Thus, our findings support the current UNAIDS recommendations that men seeking circumcision who are already HIV infected be discouraged but not refused the operation.

In addition, earlier concerns about women being exposed to increased risk due to risk compensation among circumcised men are substantially aulled. Our calculations show that it is unlikely that risk compensation following circumcision will undermine the benefits for either men or women.

We adapted two previously developed mathematical models, both of which make a number of simplifying assumptions about the pattern of sex partner contact and HIV natural history, but which have nevertheless proved useful in developing recommendations and strategic decision-making in male circumcision interventions. Application of the same analysis to two independently constructed models, parameterised for different settings, also indicates that our findings are not specific to one type of modelling approach or one population. There are similarities in the model structure (both are deterministic compartmental transmission models which include stratification by risk group and an account of mixing in sexual contact between risk groups), but substantial differences remain, besides parameterisation, such as the way that the force of infection is calculated and the assumption made about entry and exit to different risk categories. The impact of circumcision interventions is somewhat less in Kisumu (model 2) than in Zimbabwe (model 1), because the basic reproductive ratio is estimated to be higher in Kisumu (this reduces the impact of many types of intervention) and 25% of men in Kisumu are already circumcised. These results should not be interpreted as literal forecasts for either setting, as the rate of scale-up of circumcision that will be achieved is far from certain, and the imprecision in the specification of the epidemiological conditions was not fully quantified.

An important limitation is that neither model explicitly accounts for possible interactions between circumcision and other STIs. Therefore the benefits of circumcision interventions in reducing the incidence of other STIs cannot be quantified here. Any indirect effects on HIV incidence that accrue through reduced STI prevalence will also not be captured in the models, so our results may in fact underestimate the impact of the interventions. However, earlier work indicates that the strength of those indirect effects is expected to be small relative to the direct effect of circumcision on HIV acquisition (and transmission).

Indirect observational data have produced conflicting evidence on the effect of circumcision on male-to-female HIV transmission, but most studies were severely limited by a lack of knowledge on the circumcision or infection status of men. A recent meta-analysis included data from the Rakai randomised controlled trial among HIV-infected men and six longitudinal studies, with 95% CI 0.53 to 1.36 (point estimate 0.80). In this paper, we have restricted analyses to the only two longitudinal studies that directly measured rates of transmission from HIV-infected men of known circumcision status at the time of study entry to their regular partners. Both found evidence for a reduction in transmission, although small numbers limited statistical significance in each study when analysed separately. Our meta-analysis of these highly comparable datasets, however, provides statistically significant evidence of a true effect. The uncertainty in the estimated effect size was, nevertheless, fully represented in this analysis (figure 2). The Rakai trial showed no efficacy in the 2 years of follow-up of female partners after their male partners were circumcised, suggesting that it may take time for keratinisation of the scar and glans or other biological changes to develop, and here we assumed that the effect developed 2 years after the operation. Encouragingly, more data will become available from on-going HIV vaccine trials and other studies, which will help to hone our knowledge about the effect of circumcision and refining model projections.
In conclusion, projections for the impact of circumcision interventions on population-level HIV may need to be dramatically revised: the impact of male circumcision implementation could be realised much sooner and with greater cost-efficiency than had previously been thought. It is also crucial to recognise and communicate that, although male circumcision is an intervention applied to men, it brings substantial benefits for women as well. Premature resumption of sexual activity before the wound is healed or ‘compensatory’ increases in risk following circumcision are both unlikely to substantively undermine the benefits of male circumcision on HIV incidence among women or men.

Acknowledgements We thank The Wellcome Trust (TBH) and the US National Institutes of Health (grant 1R01AI083034) and Qatar National Research Fund (N PRP 99-D08-3-024) (TBH and LA-R) for funding support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Funding Wellcome Trust + NIH.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

Specialty induction for junior doctors in genitourinary/HIV medicine using an e-learning tool

Junior doctors’ specialty induction within our genitourinary medicine (GUM)/HIV department has traditionally comprised of a lecture-based programme. This covers local guidelines, runs over 2 days, three times a year, requires significant coordination and input from the multidisciplinary team and occupies our main lecture theatre, thereby interrupting the department’s educational agenda.

Training Tracker is an e-learning tool used by over 50 NHS trusts, for staff trust induction and statutory/mandatory training. Chelsea and Westminster Hospital is one such trust. Using this software, we devised, piloted and evaluated a GUM/HIV specialty online induction programme for junior doctors.

In August 2009, 12 doctors joining the specialty received the traditional lecture-based induction and completed a new e-induction programme using Training Tracker. Doctors then returned a feedback questionnaire anonymously.

The e-programme consisted of over 30 modules that delivered similar content to the traditional lectures. The modules were completed during weekly educational and non-clinical sessions over the first 4–6 weeks.

The website was accessed using a unique username and password, from work or remotely if preferred. Assistance with modules, if required, was provided by the participant’s educational supervisor.

Twelve junior doctors (four specialist registrars, two foundation year trainees, two GP trainees, two core medical trainees and two trust grade doctors) piloted the e-learning tool. All completed the evaluation form.

Doctors rated their overall level of learning from Training Tracker at 7.5/10 (median) (0=nil, 10=excellent, range 6–9). Doctors agreed that they could log on (100%), navigate the site without difficulty (100%) and that the content was useful (11/12, 92%), relevant (10/12, 89%) and of appropriate depth (11/12, 92%) and pitch (10/11, 91%) for their needs.

Only one doctor found the lecture induction preferable to the e-programme. Ten doctors (83%) found the e-modules covered everything sufficiently well.

E-learning is rapidly growing as a form of delivering training. Learning times can be reduced by 40–60% and application to the job is enhanced by 25% compared with traditional teaching methods.1,2

Using e-learning for GUM/HIV specialty induction was found to be acceptable, user friendly and could partly/wholly replace a lecture-based programme. Its use released valuable staff time and space and catered for a large intake of doctors. Added benefits include: on-demand availability, caters for staff joining outside the classic intake times, reduced information overload, enables participants to self-pace and thus caters for a range of learners, built-in anti-cheating deterrents, consistent delivery of content and universal interactivity.

S Day, M Raymont, M Mehabeer
Directorate of HIV/GUM, Chelsea and Westminster Hospital, London, UK

Correspondence to Dr Sara Day, Directorate of HIV/GUM, Chelsea and Westminster Hospital, 4th Floor St Stephens Centre, 369 Fulham Road, London, SW10 9NH, UK; saralouiseday@googlemail.com

Competing interests None declared.

Patient consent Obtained.

Provenance and peer review Not commissioned; not externally peer reviewed.

Accepted 6 December 2010

Published Online First 10 January 2011

Sex Transm Infect 2011;87:93.
doi:10.1136/sti.2010.048124

REFERENCES
Will circumcision provide even more protection from HIV to women and men? New estimates of the population impact of circumcision interventions

Timothy B Hallett, Ramzi A Alsallaq, Jared M Baeten, Helen Weiss, Connie Celum, Ron Gray and Laith Abu-Raddad

*Sex Transm Infect* 2011 87: 88-93 originally published online October 21, 2010
doi: 10.1136/sti.2010.043372

Updated information and services can be found at: [http://sti.bmj.com/content/87/2/88](http://sti.bmj.com/content/87/2/88)

These include:

**Supplementary Material**

Supplementary material can be found at: [http://sti.bmj.com/content/suppl/2011/02/14/sti.2010.043372.DC1](http://sti.bmj.com/content/suppl/2011/02/14/sti.2010.043372.DC1)

**References**

This article cites 37 articles, 4 of which you can access for free at: [http://sti.bmj.com/content/87/2/88#BIBL](http://sti.bmj.com/content/87/2/88#BIBL)

**Open Access**

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license. See: [http://creativecommons.org/licenses/by-nc/2.0/](http://creativecommons.org/licenses/by-nc/2.0/) and [http://creativecommons.org/licenses/by-nc/2.0/legalcode](http://creativecommons.org/licenses/by-nc/2.0/legalcode).

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- [Circumcision](http://group.bmj.com/group/rights-licensing/permissions) (75)
- [Urological surgery](http://journals.bmj.com/cgi/reprintform) (88)
- [Open access](http://group.bmj.com/subscribe/) (226)
- [Drugs: infectious diseases](http://sti.bmj.com/content/87/2/88) (3182)
- [HIV / AIDS](http://creativecommons.org/licenses/by-nc/2.0/with-the-license) (2514)
- [HIV infections](http://creativecommons.org/licenses/by-nc/2.0/with-the-license) (2514)
- [HIV/AIDS](http://creativecommons.org/licenses/by-nc/2.0/with-the-license) (2514)
- [Clinical trials (epidemiology)](http://creativecommons.org/licenses/by-nc/2.0/with-the-license) (160)

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)
To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/